Clinical candidates targeting the ATR–CHK1–WEE1 axis in cancer

L Gorecki, M Andrs, J Korabecny - Cancers, 2021 - mdpi.com
Simple Summary Selective killing of cancer cells is privileged mainstream in cancer
treatment and targeted therapy represents the new tool with a potential to pursue this aim. It …

Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma

N Barnaba, JR LaRocque - Cell Cycle, 2021 - Taylor & Francis
Disruption of cell cycle checkpoints has been well established as a hallmark of cancer. In
particular, the G1-S transition mediated by the cyclin D-cyclin-dependent kinase 4/6 …

Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway

J Zhang, CM Simpson, J Berner, HB Chong, J Fang… - Cell, 2023 - cell.com
Multiple anticancer drugs have been proposed to cause cell death, in part, by increasing the
steady-state levels of cellular reactive oxygen species (ROS). However, for most of these …

Targeting the DNA damage response for cancer therapy

NJ Curtin - Biochemical Society Transactions, 2023 - portlandpress.com
The DNA damage response (DDR) is an elegant system, coordinating DNA repair with cell
cycle checkpoints, that evolved to protect living organisms from the otherwise fatal levels of …

Targeting replication stress response pathways to enhance genotoxic chemo-and radiotherapy

JA Nickoloff - Molecules, 2022 - mdpi.com
Proliferating cells regularly experience replication stress caused by spontaneous DNA
damage that results from endogenous reactive oxygen species (ROS), DNA sequences that …

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling …

M Bakhtiyari, M Liaghat, F Aziziyan… - Cell Communication and …, 2023 - Springer
Acute myeloid leukemia (AML) comprises a multifarious and heterogeneous array of
illnesses characterized by the anomalous proliferation of myeloid cells in the bone marrow …

Transcriptional silencing of MCL-1 through cyclin-dependent kinase inhibition in acute myeloid leukemia

R Tibes, JM Bogenberger - Frontiers in Oncology, 2019 - frontiersin.org
Acute myeloid leukemia (AML) is the most common adult acute leukemia. Survival remains
poor, despite decades of scientific advances. Cytotoxic induction chemotherapy regimens …

HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition

C Moison, JF Spinella, J Chagraoui… - Blood …, 2022 - ashpublications.org
High-mobility group AT-hook 2 (HMGA2) is a nonhistone chromatin-binding protein that is
normally expressed in stem cells of various tissues and aberrantly detected in several tumor …

Inhibition of CHK 1 (checkpoint kinase 1) elicits therapeutic effects in pulmonary arterial hypertension

A Bourgeois, S Bonnet, S Breuils-Bonnet… - … , and vascular biology, 2019 - Am Heart Assoc
Objective: Pulmonary arterial hypertension (PAH) is a debilitating disease associated with
progressive vascular remodeling of distal pulmonary arteries leading to elevation of …

A Selective Nano Cell Cycle Checkpoint Inhibitor Overcomes Leukemia Chemoresistance

J Sun, F Xia, S Zhang, B Zhang, Y Guan, X Hu, P Xue… - Small, 2023 - Wiley Online Library
Cell cycle checkpoint activation promotes DNA damage repair, which is highly associated
with the chemoresistance of various cancers including acute myeloid leukemia (AML) …